Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Scheduled for non-emergent, hepatic surgery~* Presence of an appropriate target bleeding site (TBS) as defined by the protocol~Major Exclusion Criteria:~* Subject will be undergoing a laparoscopic hepatic procedure where the Hemostatic Patch will be delivered and applied through a trocar~* In subjects with documented history of cirrhosis, subject has uncorrected platelet count \<60,000 per mm³ as determined by laboratory tests performed immediately prior to surgery~* Subject has severe coagulopathy defined as INR \> 2.0~* Subject has Total Bilirubin \>2.5mg/dL~* Subject has an active local infection at the Target Bleeding Site~* Study procedure involves a liver transplant recipient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veriset Hemostatic Patch (Type: EXPERIMENTAL): Veriset Hemostatic Patch
- Fibrin Sealant (TachoSil®) (Type: ACTIVE_COMPARATOR): Fibrin Sealant (TachoSil®)

Based on this trial design, predict the completion outcome and termination type (if applicable).